These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 18625435)

  • 1. Hepatitis C virus entry and neutralization.
    Stamataki Z; Grove J; Balfe P; McKeating JA
    Clin Liver Dis; 2008 Aug; 12(3):693-712, x. PubMed ID: 18625435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies.
    Timpe JM; Stamataki Z; Jennings A; Hu K; Farquhar MJ; Harris HJ; Schwarz A; Desombere I; Roels GL; Balfe P; McKeating JA
    Hepatology; 2008 Jan; 47(1):17-24. PubMed ID: 17941058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells.
    Witteveldt J; Evans MJ; Bitzegeio J; Koutsoudakis G; Owsianka AM; Angus AG; Keck ZY; Foung SK; Pietschmann T; Rice CM; Patel AH
    J Gen Virol; 2009 Jan; 90(Pt 1):48-58. PubMed ID: 19088272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor.
    Bartosch B; Vitelli A; Granier C; Goujon C; Dubuisson J; Pascale S; Scarselli E; Cortese R; Nicosia A; Cosset FL
    J Biol Chem; 2003 Oct; 278(43):41624-30. PubMed ID: 12913001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD81 is an entry coreceptor for hepatitis C virus.
    Cormier EG; Tsamis F; Kajumo F; Durso RJ; Gardner JP; Dragic T
    Proc Natl Acad Sci U S A; 2004 May; 101(19):7270-4. PubMed ID: 15123813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A view of the E2-CD81 interface at the binding site of a neutralizing antibody against hepatitis C virus.
    Harman C; Zhong L; Ma L; Liu P; Deng L; Zhao Z; Yan H; Struble E; Virata-Theimer ML; Zhang P
    J Virol; 2015 Jan; 89(1):492-501. PubMed ID: 25339761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The dynamics of hepatitis C virus binding to platelets and 2 mononuclear cell lines.
    Hamaia S; Li C; Allain JP
    Blood; 2001 Oct; 98(8):2293-300. PubMed ID: 11588022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The tight junction proteins claudin-1, -6, and -9 are entry cofactors for hepatitis C virus.
    Meertens L; Bertaux C; Cukierman L; Cormier E; Lavillette D; Cosset FL; Dragic T
    J Virol; 2008 Apr; 82(7):3555-60. PubMed ID: 18234789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI.
    Dreux M; Pietschmann T; Granier C; Voisset C; Ricard-Blum S; Mangeot PE; Keck Z; Foung S; Vu-Dac N; Dubuisson J; Bartenschlager R; Lavillette D; Cosset FL
    J Biol Chem; 2006 Jul; 281(27):18285-95. PubMed ID: 16675450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C virus entry: potential receptors and their biological functions.
    Cocquerel L; Voisset C; Dubuisson J
    J Gen Virol; 2006 May; 87(Pt 5):1075-1084. PubMed ID: 16603507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Steps and Routes of HCV Infection: The Great Promise of New Anti-Viral Targets.
    Crema A; Ponzetto A; Clementi M; Carloni G
    Curr Drug Targets; 2015; 16(7):757-70. PubMed ID: 25694122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms.
    Mankowski MC; Kinchen VJ; Wasilewski LN; Flyak AI; Ray SC; Crowe JE; Bailey JR
    Proc Natl Acad Sci U S A; 2018 Jan; 115(1):E82-E91. PubMed ID: 29255018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C virus utilizes VLDLR as a novel entry pathway.
    Ujino S; Nishitsuji H; Hishiki T; Sugiyama K; Takaku H; Shimotohno K
    Proc Natl Acad Sci U S A; 2016 Jan; 113(1):188-93. PubMed ID: 26699506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [CD81 Present status and prospect of HCV receptor].
    Liu MX; Wang FS
    Zhonghua Gan Zang Bing Za Zhi; 2002 Aug; 10(4):311-3. PubMed ID: 12223154
    [No Abstract]   [Full Text] [Related]  

  • 15. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy.
    Lupberger J; Zeisel MB; Xiao F; Thumann C; Fofana I; Zona L; Davis C; Mee CJ; Turek M; Gorke S; Royer C; Fischer B; Zahid MN; Lavillette D; Fresquet J; Cosset FL; Rothenberg SM; Pietschmann T; Patel AH; Pessaux P; Doffoël M; Raffelsberger W; Poch O; McKeating JA; Brino L; Baumert TF
    Nat Med; 2011 May; 17(5):589-95. PubMed ID: 21516087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The roles of CD81 and glycosaminoglycans in the adsorption and uptake of infectious HCV particles.
    Morikawa K; Zhao Z; Date T; Miyamoto M; Murayama A; Akazawa D; Tanabe J; Sone S; Wakita T
    J Med Virol; 2007 Jun; 79(6):714-23. PubMed ID: 17457918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary hepatocytes of Tupaia belangeri as a potential model for hepatitis C virus infection.
    Zhao X; Tang ZY; Klumpp B; Wolff-Vorbeck G; Barth H; Levy S; von Weizsäcker F; Blum HE; Baumert TF
    J Clin Invest; 2002 Jan; 109(2):221-32. PubMed ID: 11805134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of single nucleotide polymorphisms in the essential HCV entry factor CD81 on HCV infectivity and neutralization.
    Deest M; Westhaus S; Steinmann E; Manns MP; von Hahn T; Ciesek S
    Antiviral Res; 2014 Jan; 101():37-44. PubMed ID: 24211330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HCV infection by cell-to-cell transmission: choice or necessity?
    Carloni G; Crema A; Valli MB; Ponzetto A; Clementi M
    Curr Mol Med; 2012 Jan; 12(1):83-95. PubMed ID: 22082483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus.
    Lavillette D; Tarr AW; Voisset C; Donot P; Bartosch B; Bain C; Patel AH; Dubuisson J; Ball JK; Cosset FL
    Hepatology; 2005 Feb; 41(2):265-74. PubMed ID: 15660396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.